Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma
Authors
Keywords
-
Journal
PHARMACOECONOMICS
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-12-13
DOI
10.1007/s40273-018-0740-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties
- (2018) Rumona Dickson et al. Applied Health Economics and Health Policy
- Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
- (2017) Robert Marcus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
- (2017) Nasuh C. Büyükkaramikli et al. PHARMACOECONOMICS
- Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
- (2017) Nasuh C. Büyükkaramikli et al. PHARMACOECONOMICS
- Early event status informs subsequent outcome in newly diagnosed follicular lymphoma
- (2016) Matthew J. Maurer et al. AMERICAN JOURNAL OF HEMATOLOGY
- The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis
- (2016) Eva Kaltenthaler et al. HEALTH TECHNOLOGY ASSESSMENT
- Follicular lymphoma: 2015 update on diagnosis and management
- (2015) Arnold Freedman AMERICAN JOURNAL OF HEMATOLOGY
- Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
- (2015) Carla Casulo et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States
- (2014) Loretta J. Nastoupil et al. LEUKEMIA & LYMPHOMA
- Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data
- (2013) Nicholas R. Latimer MEDICAL DECISION MAKING
- Non-Hodgkin lymphoma
- (2012) Kate R Shankland et al. LANCET
- Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
- (2010) Gilles Salles et al. LANCET
- An Analysis of NICEʼs ‘Restricted’ (or ‘Optimized’) Decisions
- (2010) Phill OʼNeill et al. PHARMACOECONOMICS
- Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
- (2009) Massimo Federico et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now